s6y

Connect Biopharma Holdings Ltd

Ticker
CNTB
CIK
1835268
Industry
Pharmaceutical Preparations

Financials 8

  1. 10-Q Quarterly Report for period ending Sep 30, 2026
  2. 10-Q Quarterly Report for period ending Jun 30, 2026
  3. 10-Q Quarterly Report for period ending Mar 31, 2026
  4. 10-K Annual Report for period ending Dec 31, 2025
  5. 10-Q Quarterly Report for period ending Sep 30, 2025
  6. 10-Q Quarterly Report for period ending Jun 30, 2025
  7. 10-Q Quarterly Report for period ending Mar 31, 2025
  8. 10-K Annual Report for period ending Dec 31, 2024

News 21

  1. 8-K Current report filing
  2. 8-K Current report filing
  3. 8-K Current report filing
  4. 8-K Current report filing
  5. 8-K Current report filing
  6. 8-K Current report filing
  7. 8-K Current report filing
  8. 8-K Current report filing
  9. 8-K Current report filing
  10. 8-K Current report filing

All 21 news filings

Ownership 39

  1. 4 Statement of changes in beneficial ownership of securities
  2. 4 Statement of changes in beneficial ownership of securities
  3. 4 Statement of changes in beneficial ownership of securities
  4. 4 Statement of changes in beneficial ownership of securities
  5. 4 Statement of changes in beneficial ownership of securities
  6. 4 Statement of changes in beneficial ownership of securities
  7. 4 Statement of changes in beneficial ownership of securities
  8. 4 Statement of changes in beneficial ownership of securities
  9. 3 Initial statement of beneficial ownership of securities
  10. 3 Initial statement of beneficial ownership of securities

All 39 ownership filings

Prospectus 10

  1. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  2. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  3. S-8 Initial registration statement for securities to be offered to employees pursuant to employee benefit plans
  4. 424B4 Prospectus filed pursuant to Rule 424(b)(4)
  5. DRSLTR Correspondence Related to Draft Registration Statement
  6. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  7. DRSLTR Correspondence Related to Draft Registration Statement
  8. DRS/A Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy
  9. DRSLTR Correspondence Related to Draft Registration Statement
  10. DRS Draft registration statement submitted by Emerging Growth Company under Securities Act Section 6(e) or by Foreign Private Issuer under Division of Corporation Finance policy

Other 121

  1. SCHEDULE 13G/A
  2. SCHEDULE 13G/A
  3. SCHEDULE 13G
  4. SCHEDULE 13G/A
  5. SCHEDULE 13G/A
  6. EFFECT Notice of Effectiveness
  7. CORRESP A correspondence can be sent as a document with another submission type or can be sent as a separate submission.
  8. UPLOAD Letter (PDF)
  9. SCHEDULE 13G/A
  10. F-3 Registration statement for specified transactions by certain foreign private issuers

All 121 other filings